News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Patients use ChatGPT for therapy when appointments unavailable
General-purpose AI lacks clinical architecture to safely handle mental health conversations, creating risks that purpose-built tools can address.
IHH Healthcare moves finance and HR systems to Oracle Cloud
Asia's largest private hospital group consolidates legacy systems across 190 facilities in 10 countries onto Oracle Fusion platform.
Healthcare IT outages expose compliance gaps in backup plans
System downtime playbooks often miss regulatory requirements, leaving hospitals exposed during critical incidents.
Abridge expands AI documentation from doctors to nurses
The ambient AI platform rolls out weekly to nursing teams at Mayo, Johns Hopkins, and five other health systems after two years of co-development.
Urgent care AI scribes cut documentation time 40%, add $300K revenue
Experity's AI scribe reduced daily documentation from 395 to 240 minutes across 450 clinics, enabling three extra patients per day.
Sarepta gene therapy sales drop despite beating estimates
Elevidys revenue declined further but topped Wall Street forecasts as investors shift focus to the company's RNA pipeline.
Odyssey bags $279M IPO after withdrawing last year's attempt
The autoimmune drugmaker priced 15.5M shares at $18 each, joining 2024's string of $250M+ biotech offerings after pulling its 2023 filing.
Lilly, Gilead drive 2026 pharma M&A surge past 2025 levels
Deal volume jumps as Big Pharma targets cancer and autoimmune drugs, with Lilly and Gilead leading acquisition activity.
FDA delays Leqembi subcutaneous approval by three months
Biogen and Eisai's weekly injection version of their Alzheimer's drug faces August review after regulators request major amendments to the filing.
Odyssey raises $279M in IPO for autoimmune drugs
The biotech company priced its public offering and begins trading Friday on Nasdaq, joining a wave of biotech IPO activity.
Capricor sues Nippon Shinyaku over Duchenne drug deal
Biotech files lawsuit over distribution agreement for deramiocel cell therapy, citing pricing and launch issues.
Natalie Holles named CEO after Third Harmonic shutdown
Former Third Harmonic CEO takes new leadership role following her previous company's closure, though details remain behind paywall.